Examples of using Two phase in English and their translations into Norwegian
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Sevbalsamol Two phase without rinsing.
The efficacy of pasireotide intramuscular use has been demonstrated in two phase III, multicentre studies.
Two Phase III randomised, multicentre, double-blind, placebo-controlled studies were conducted in patients with cervical dystonia.
In addition, children have been treated in two phase I studies and one phase II study.
The clinical evidence for the efficacy and safety of ticagrelor is derived from two phase 3 trials.
ADCETRIS was administered as monotherapy in 160 patients in two phase 2 studies in patients with relapsed or refractory HL or sALCL.
A total of 427 patients were randomised to receive OZURDEX and 426 to receive sham in the two Phase III studies.
In addition, children have been treated in two phase I studies(in patients with CML or Ph+ acute leukaemia) and one phase II study.
Elevated fasting glucose level was the most frequently reported grade 3/4 laboratory abnormality in the two phase III studies.
And 13% of eribulin treated patients received G-CSF in the two phase 3 breast cancer studies Studies 305 and 301, respectively.
Assessment of adverse reactions is based on two Phase 3 studies(study 312-0116 and study 312-0119) and six Phase 1 and 2 studies.
Table 1 Adverse reactions by preferred term for pasireotide intramuscular use in the two phase III studies in acromegaly patients.
You know fundamental mechanisms for two phase flow in porous media and how numerical models can be used to understand the observed pattern formations.
In addition, paediatric patients have been treated in two phase I studies and one phase II study.
Two Phase 3 and one Phase 2 double-blind, parallel-group, placebo-controlled studies were performed to assess the indication of sodium oxybate for fibromyalgia.
Can measure 3 phase voltage, 3 phase current,average voltage, two phase active power and total power.
In two Phase III randomised-controlled studies patients with non-Hodgkin's lymphoma or multiple myeloma received Mozobil 0.24 mg/kg or placebo on each evening prior to apheresis.
In addition, children and adolescents have been treated in two phase I studies(in patients with CML or Ph+ acute leukaemia) and one phase II study.
The pharmacokinetic parameters quoted below are based on population parameter estimates for the 563 patients who received Benlysta 10 mg/kg in the two Phase III studies.
Adverse Reactions(ARs) have been collected from one phase I study with healthy subjects(n 28) and two phase III studies in patients with primary immunodeficiency(n 100) with Hizentra.
Antibodies directed against the belatacept molecule were assessed in 796 kidney transplant recipients(551 of these treated for at least 3 years) in the two Phase 3 studies.
Before the third dose of Eurartesim, in one of the two Phase III studies 3/767 patients(0.4%) were reported to have a QTcF value of> 500 ms versus none in the comparator group.
Of these patients, 248 are from the Phase 3 study in previously untreated CML patients, 570 and52 are from two Phase 1/2 studies in previously treated Ph+ leukaemias.
Lenalidomide has been evaluated in two phase III studies in newly diagnosed multiple myeloma and two phase III studies in relapsed refractory multiple myeloma as described below.
Table 3 shows the results of a prospectively planned combined analysis of the CDI recurrence rates in pre-specified subgroups of patients at high risk for CDI recurrence across the two Phase 3 Trials.
Two Phase Heat Transfer Systems- with natural refrigerants such as Propane used as the working fluid to transfer heat and provide cooling in a variety of applications for higher efficiencies.
Over 800 patients with moderate to severe symptoms of BPH(International Prostate Symptom Score, IPSS, baseline value≥13)received silodosin 8 mg once daily in two Phase III placebo-controlled clinical studies conducted in the United States and in one placebo- and active-controlled clinical study conducted in Europe.
In the two Phase III studies in non-Hodgkin's lymphoma and multiple myeloma patients(AMD3100-3101 and AMD3100-3102, respectively), a total of 301 patients were treated in the Mozobil and G-CSF group and 292 patients were treated in the placebo and G-CSF group.
The safety population of Gilenya is derived from two Phase III placebo-controlled clinical studies and one Phase III active-controlled clinical study in patients with relapsing remitting multiple sclerosis.